Release Date: 23 January 2025
Sabestomig (AZD7789) is a bispecific monoclonal antibody developed by AstraZeneca, designed to target two key immune checkpoints, programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and mucin domain 3 (TIM-3)...
Release Date: 23 January 2025
PM8002 is a next-generation bispecific antibody developed to block both the PD-L1 and VEGF pathways, offering a novel approach to treating solid tumors. The antibody specifically targets the PD-L1 pathway, a key immune ch...
Release Date: 23 January 2025
Anbenitamab (KN026) is a bispecific antibody developed by Alphamab Oncology that targets the HER2 receptor, a key driver in the progression of several cancers, including breast cancer and gastroesophageal junction adenoca...
Release Date: 23 January 2025
CTX 009, also known as Tovecimig, is a bispecific antibody being developed by TRIGR Therapeutics, a subsidiary of Compass Therapeutics, for the treatment of solid tumors, including biliary cancer and colorectal cancer. Th...
Release Date: 23 January 2025
SI B001 is a bispecific antibody under development by Sichuan Baili Pharmaceutical (Biokin Pharmaceutical) in China and its subsidiary SystImmune in the United States. It is being investigated for the treatment of solid t...
Release Date: 23 January 2025
Mim 8 is a next-generation coagulation factor VIII (FVIII) mimetic antibody developed by Novo Nordisk for the treatment of hemophilia A. Hemophilia A is a genetic disorder characterized by a deficiency in FVIII, which is ...
Release Date: 23 January 2025
Erfonrilimab, formerly known as KN046, is a promising immune modulator and bispecific antibody being developed by Alphamab. This innovative therapeutic is designed to simultaneously target two key immune checkpoint protei...
Release Date: 23 January 2025
Silevimig (GR1801) is a novel bispecific antibody developed by Shanghai Genrix Biopharmaceuticals, designed as a therapeutic agent for rabies. This human bispecific antibody combines two monoclonal antibodies, A2 and B353...
Release Date: 23 January 2025
RC28-E, developed by RemeGen and Rongchang Biopharmaceutical, is an innovative bispecific antibody designed for the treatment of neovascular age-related macular degeneration (AMD). This novel therapy simultaneously target...
Release Date: 23 January 2025
Efdamrofusp alfa, previously known as IBI 302, is a recombinant fully human bispecific monoclonal antibody developed by Innovent Biologics for the treatment of wet age-related macular degeneration (AMD). Wet AMD is a lead...
Release Date: 23 January 2025
Catumaxomab is an innovative trifunctional monoclonal antibody being developed by Linton Pharm for the treatment of various cancers, with a focus on malignant ascites. This unique antibody targets two key cell surface ant...
Release Date: 23 January 2025
Volrustomig, previously known as MEDI 5752, is a monovalent bispecific human IgG1 monoclonal antibody being developed by AstraZeneca (formerly Medimmune) for the treatment of various cancers. It is designed to target two ...
Release Date: 23 January 2025
BL-B01D1 is a novel and potentially first-in-class bispecific antibody-drug conjugate (ADC) developed by SystImmune. It is designed to target both epidermal growth factor receptor (EGFR) and human epidermal growth factor ...
Release Date: 23 January 2025
Rilvegostomig, previously known as AZD2936, is an innovative bispecific antibody currently under development by Compugen and AstraZeneca. It is derived from Compugen’s COM902 program and specifically targets two imm...
Release Date: 16 January 2025
Antibody-drug conjugates (ADCs) are emerging as a promising therapeutic approach for skin cancer, particularly melanoma, though no ADC has been approved for this indication as of October 2024. Melanoma, a highly aggressiv...